In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Members will get treatment till condition progression or perhaps the individuals are not able to tolerate the study drugs. For all stream cytometry experiments, ten,000 cells per replicate have been analyzed, https://paulineb332mzj5.oneworldwiki.com/user